Drug Trial Radar · NCT02577523
A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: May 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Dec 29, 2015
Primary completion
Dec 20, 2016
Study completion Jan 31, 2017
Sponsor
- Lead sponsor
- NeuroDerm Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 16, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, parallel-group, rater-blinded, randomized clinical study in subjects with advanced PD investigating the efficacy, PK, safety and tolerability of continuous SC infusion of 2 dosing regimens of ND0612H, a solution of LD/CD delivered via a pump system as a continuous SC infusion, compared to standard oral LD/CD. After screening, subjects will undergo 1 day of standard oral LD/CD inpatient dosing followed by 2 days of inpatient treatment with 1 of 2 randomly allocated (1:1 randomization ratio) dosing regimens of ND0612H continuous SC infusion. Subjects will then continue on a maintenance dose of the assigned ND0612H dosing regimen for the next 25 days. A safety visit will be performed 4 weeks after the last SC administration of the study drug for a total of about 2.5 months of participation for each subject enrolled into the trial.
Conditions
- Parkinson's Disease
Interventions
ND0612 (Levodopa/Carbidopa solution)Drug
The total daily dose of levodopa/carbidopa 720/90 mg. Device: CRONO TWIN pump system.
ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CDDrug
The total daily dose levodopa/carbidopa from ND0612 538/67 mg. Morning dose of oral IR-LD/CD 150/15 mg. Device: CRONO TWIN pump system.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Daily "OFF" TimeTime frame: Baseline to Day 28
Locations
11 sites in 4 countries. Site status is shown where the registry gives one.
Northwestern University
Chicago, Illinois
QUEST Research Institute
Farmington Hills, Michigan
University of Cincinnati
Cincinnati, Ohio
Medical University Innsbruck
Innsbruck, Austria
Rabin Medical Center
Petah Tikva, Israel
Chaim Sheba Medical Center
Ramat Gan, Israel
Sourasky Medical Center
Tel Aviv, Israel
University Foundation
Chieti, Italy
AOU Pisa
Pisa, Italy
IRCCS San Raffaele Pisana
Rome, Italy
Fondazione Ospedale San Camillo - I.R.C.C.S.
Venice, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.